On Thursday shares of Acceleron Pharma, Inc. (NASDAQ:XLRN) closed at $27.65. -Acceleron Pharma Inc. (NASDAQ:XLRN), announced that Acceleron and its collaboration partner, Celgene Corporation, plan to initiate a Phase 3 program with luspatercept in myelodysplastic syndromes and beta-thalassemia by year-end 2015.
La Jolla Pharmaceutical Co. (NASDAQ:LJPC) in last trading activity fell -10.67% to close at $19.01. Company weekly performance is -21.90% while its quarterly performance stands at -13.51%. La Jolla Pharmaceutical Co. (NASDAQ:LJPC) is -23.62% away from its 52 week high. La Jolla Pharmaceutical Co. (NASDAQ:LJPC) on Wednesday reported a loss of $9 million in its first quarter. The San Diego-based company said it had a loss of 59 cents per share.
On last trading day ModusLink Global Solutions, Inc. (NASDAQ:MLNK) fell -2.23% to close at $3.50. Its volatility for the week is 2.63% while volatility for the month is 2.78%. MLNK’s sales growth for past 5 years was -6.30% and its EPS growth for past 5 years was 40.80%. ModusLink Global Solutions, Inc. (NASDAQ:MLNK) monthly performance is -9.09%.
Intellicheck Mobilisa, Inc. (NYSEMKT:IDN) has 43.77% insider ownership while its institutional ownership stands at 23.00%. In last trading activity company’s stock closed at $1.56. Intellicheck Mobilisa, Inc. (NYSEMKT:IDN), announced the hiring of Howard Green to accelerate the company’s plan for profitable growth and expansion into new markets. Effective immediately, the tech industry marketing leader will drive Intellicheck Mobilisa’s expanded marketing initiatives with a focus on go-to-market strategies and creating new product commercialization opportunities.
On Thursday shares of The Medicines Company (NASDAQ:MDCO) closed at $25.61. Company’s sales growth for last 5 years was 12.40% and EPS growth for next 5 years is recorded as 10.00%. Medicines Co. (NASDAQ:MDCO) announced that the U.S. Food and Drug Administration has approved RAPLIXA (fibrin sealant) and the RaplixaSpray device to provide adjunctive hemostasis for mild to moderate bleeding in adults undergoing surgery when control of bleeding by standard surgical techniques (such as suture, ligature and cautery) is ineffective or impractical.
LinkedIn Corporation (NYSE:LNKD) in last trading activity decreased -1.95% to close at $252.13. Company weekly performance is -1.60% while its quarterly performance stands at 13.04%. LinkedIn Corporation (NYSE:LNKD) is -8.71% away from its 52 week high. LinkedIn Corporation (NYSE:LNKD), reported its results for the first quarter of 2015. Revenue for the first quarter was $638 million, an increase of 35% compared to $473 million in the first quarter of 2014.